ELIQUIS® (apixaban) approved in Europe for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
20 November 2012 | By Bristol-Myers Squibb Company
The EC has approved ELIQUIS®...
List view / Grid view
20 November 2012 | By Bristol-Myers Squibb Company
The EC has approved ELIQUIS®...
4 September 2012 | By F T I Consulting
The European Commission has granted European market authorization for the medicinal product teduglutide...
28 August 2012 | By AstraZeneca
European Commission approves ZINFORO™...
25 July 2012 | By H. Lundbeck A/S
The European Commission has issued a Statement of Objections to Lundbeck...
27 April 2012 | By GlaxoSmithKline
The European Commission has granted marketing authorisation for Nimenrix...
11 April 2012 | By
The European Commission has approved HUMIRA®...
27 February 2012 | By Novartis
The European Commission has approved an update to the Glivec® (imatinib)* label...
21 February 2012 | By AstraZeneca
Marketing authorisation for CAPRELSA® (vandetanib) granted...
6 February 2012 | By Chamberlain Healthcare PR
The European Commission has approved the use of Galvus® (vildagliptin)...
5 December 2011 | By Novartis
The European Commission has approved Galvus® (vildagliptin) (50 mg once a day) for the treatment of type 2 diabetes patients with moderate or severe renal impairment...
29 November 2011 | By AstraZeneca
The European Commission has granted marketing authorisation for KOMBOGLYZE™...
28 November 2011 | By Daniel J Edelman Ltd
The European Commission has granted marketing authorisation for EDURANT® (rilpivirine)...
28 November 2011 | By Gilead Sciences Inc
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Eviplera®...
17 November 2011 | By GlaxoSmithKline
GSK welcomes the EC’s commitment...
15 November 2011 | By Amgen
The EC has approved a variation to the marketing authorization for Vectibix®...